adijas
6 years ago
8k out friday ah about PR that never hit OTCM https://www.otcmarkets.com/filing/html?id=12934395&guid=t8oEU6UER5vtath
Ember Therapeutics Enters Into Agreement to Divest OP-1 Portfolio Program to Viscogliosi Brothers, LLC
Published 3:53 PM ET Thu, 16 Aug 2018 PR Newswire
NEW YORK, Aug. 16, 2018 /PRNewswire/ -- Ember Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7), announced today that it has entered into a letter of intent with Viscogliosi Brothers, LLC (VB), a private equity investment firm focused on developing innovative neuromusculoskeletal technologies, for the sale of its OP-1 product family and related assets, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in orthopaedic bone applications.
Ember Therapeutics had acquired the exclusive, worldwide license to the BMP-7 and OP-1 portfolio and associated intellectual property from Stryker Corporation in 2014. The previously commercialized OP-1 product portfolio had at one point generated approximately $100M in annual revenues for Stryker and had been viewed as a formidable competitor to Medtronic's Infuse.
The transaction is expected to close in late Q3 or Q4 of this year and is subject to financing. "This transaction allows Ember to continue to focus on our exciting late stage osteoarthritis (OA) program which offers the potential of addressing the actual cause of this debilitating disease by regrowing cartilage in the knee. OP-1, a related product for bone, has an immense amount of potential as has been previously used in over 50,000 patients," stated Joseph Hernandez, Executive Chairman of Ember Therapeutics. "We are excited to be working with the Viscogliosi Brothers in their efforts to commercially relaunch these products."
"We believe bone repair and regeneration is the future of orthopaedic healthcare," stated Anthony G. Viscogliosi, principal of Viscogliosi Brothers, LLC. "VB is delighted to have access once again to the previously commercialized OP-1 product family formerly owned by Stryker Biotech. This is the second publicly announced step VB has taken in the direction of assembling what we believe will be the leading global portfolio of BMP technology for stimulating bone growth."
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a pharmaceutical company developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has two commercial stage products and a late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
About Viscogliosi Brothers, LLC
Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in New York City, in 1999, Viscogliosi Brothers, LLC (VB), is a family office holding company specializing in venture capital, private equity and merchant banking in the neuro-musculoskeletal/orthopedic industry.
VB's vision is dedicated to improving healthcare and the quality of life for humanity by finding innovative orthopedic concepts and supporting them to become sustainable technologies that can be commercialized globally to lead the evolution in orthopedic standards of care.
To accomplish this vision, VB discovers technologies, creates products and develops, builds, operates and finances companies founded on innovative and "life changing" technologies. VB principals have participated in more than 300 transactions, have invested in more than 20 companies and have formed more than ten funds.
Companies and funds that VB participated in have generated more than $1.5 billion in exit proceeds for investors through 14 exits in the last 18 years. Through its portfolio companies VB has defined 7 new orthopedic industry categories and its investments have helped commercialize more than 75 medtech devices, including eleven number one orthopedic technologies in seven market leading businesses.
VB orthopedic portfolio companies' products have been implanted in nearly 300,000 people in more than 70 countries globally.
For more information, please visit www.vbllc.com.
rich pearl
7 years ago
i was doing a little browsing and noticed EMBT had an 8k on July 12th.
what's with this stock? i have a small position tucked inside my 'Tomorrow' drawer, and i'm wondering if i should lock it instead inside a time capsule. its come down to .25 x .35, and the minimalist 2500 shares offered was bought, but i notice that didn't take out the ask. obviously they're still doing business (of a sort,) but the stock itself has either gone into hibernation mode, or is inert.
i'm trying to patiently wait this one out, but i'm feeling rather poorly at the moment.
::sigh:
rich
*******************
On May 19, 2017, Ember Therapeutics, Inc. (โEmber Therapeuticsโ) entered into a Contribution Agreement (โDermaSilk Agreementโ) with DermaSilk Brands, Inc. (โDermaSilkโ), a Delaware corporation. Pursuant to the DermaSilk Agreement, DermaSilk acquired the sole ownership interest in DermaSilk Brands business, including all assets and liabilities related thereto, and DermaSilk became a wholly owned subsidiary of Ember Therapeutics. The DermaSilk Agreement isa ttached as Exhibit 99.1.
Also on May 19, 2017, Ember Therapeutics entered into a Contribution Agreement (โMigralex Agreementโ) with Migralex, Inc. (โMigralexโ) a Delaware corporation. Pursuant to the Migralex Agreement, Migralex acquired the sole ownership interest in the Migralex business, including all assets and liabilities related thereto, and Migralex became a wholly owned subsidiary of Ember Therapeutics. The MigralexAgreement is attached as Exhibit 99.1.
************
adijas
8 years ago
8k out.
Item 1.01 Entry Into A Material Definitive Agreement
On September 8, 2016, we entered into an Asset Purchase Agreement (the "Agreement") with Midwood Distributors, Inc., a New York corporation ( "Midwood Distributors"). Under the Agreement, we acquired all assets related to Dermasilk Brands, a line of anti-aging skin care products.
Under the Agreement, we have acquired all material assets currently owned by Dermasilk, including all inventory, raw materials, work in process, packaging, the toll free number, hardware and software used for ordering and customer support, all intellectual property, websites, domain names, accounts receivable and vendor credits, contracts, and all marketing and promotional information and materials.
The purchase price for the Dermasilk assets consisted of common stock and warrants, paid as follows:
โข 2,105,263 shares of common stock at purchase price of $0.95.
adijas
8 years ago
NEWS!!
NEW YORK , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York -based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilkโข Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid , CVS, Wal-Mart and K-Mart .
As part of the transaction, all assets from Dermasilk Brands, Inc. will be transferred to Ember Therapeutics, Inc.
โThis is our third acquisition this year. The addition of the Dermasilkโข brand of products to our product line will allow us to expand on our current relationship with major retailers and provide additional revenues to Ember. Dermasilk products have a large customer following and are developed using the highest cutting edge science,โ said Joseph Hernandez , Executive Chairman of Ember Therapeutics, Inc. โThe revenues generated by these products and Migralexโข, our other commercially available product, will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.โ
Dermasilkโข products are currently available at Rite-Aid , CVS, Wal-Mart , K-Mart , local pharmacies, and online at jet.com and the product website www.dermasilkbrands.com. To learn more about Dermasilkโข please access www.dermasilkbrands.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.